- Home
- LYEL vs ADCT Comparison
LYEL vs ADCT Comparison
Compare LYEL & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LYEL | ADCT |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 490.1M | 484.4M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | LYEL | ADCT |
|---|---|---|
| Price | $23.70 | $4.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $30.60 | $7.75 |
| AVG Volume (30 Days) | 74.3K | ★ 741.8K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.86 |
| EPS | N/A | ★ N/A |
| Revenue | $36,000.00 | ★ $81,357,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16,285.34 | $66.49 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $0.39 | $1.20 |
| 52 Week High | $45.00 | $4.98 |
Technical Indicators
Market Signals| Indicator | LYEL | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 55.08 | 64.25 |
| Support Level | $21.27 | $3.28 |
| Resistance Level | $27.30 | $4.77 |
| Average True Range (ATR) | 1.71 | 0.27 |
| MACD | 0.43 | 0.07 |
| Stochastic Oscillator | 74.68 | 67.28 |
Price Performance
Historical ComparisonAbout LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).